Case study reveals dupilumab significantly improves pruritus and rash in a patient with grover's disease, highlighting potential immune-mediated causes.
Grover's disease (GD) is a pruritic skin condition characterized by erythematous, scaly papules on the trunk, often resolving spontaneously but sometimes becoming persistent and difficult to manage. In this case study, we discuss a 73-year-old male with treatment-resistant GD who experienced significant improvement with dupilumab injections. Within two weeks, the patient reported noticeable improvement in pruritus and rash, with complete resolution achieved after five months of continued treatment and no notable adverse effects. This case can highlight dupilumab as a promising option for refractory GD, as well as support the hypothesis of an immune-mediated pathogenesis of GD.
No takes yet. Share an insight, caveat, or question.
McCarter et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: